Israeli cardiac AI startup UltraSight raises $24 million to expand across US hospitals

UltraSight has raised $24 million in Series B2 financing to expand its AI-guided cardiac ultrasound platform across U.S. health systems and develop new workflows for intensive care and circulatory support settings, the company announced Wednesday.

The financing was led by Alive HealthTech Growth Fund, with participation from Deep Insight, Star51 Capital, Connecticut Innovations and eHealth Ventures. Existing investors Mayo Clinic Ventures, NYU and Iron Nation also joined the round.

UltraSight said the funding will support wider adoption of its Echosystem platform in the United States and the development of additional tools for clinical settings where rapid imaging can directly affect treatment decisions.

The company’s platform combines structured training, real-time AI guidance and advanced analytics to help trained clinical providers perform focused echocardiography examinations under qualified physician oversight.

“We are entering this next stage as our FDA-cleared portfolio continues to expand to support broader cardiac imaging workflows,” said Davidi Vortman, CEO and co-founder of UltraSight. “This financing will help our efforts to translate that momentum into wider market adoption, deeper strategic collaborations and greater access to high-quality cardiac ultrasound – expediting care for patients who simply cannot afford to wait.”

UltraSight said its Echosystem is currently deployed at more than 10 commercial sites, including intensive care settings.

The company is also pointing to new clinical evidence supporting the use of AI guidance by clinicians who are not trained sonographers.

A study published in JAMA Cardiology found that novice operators using AI-guided cardiac ultrasound were able to acquire images used for automated detection of moderate or greater aortic stenosis, with 93% sensitivity and 96% specificity.

UltraSight said the findings support the potential use of AI-guided ultrasound to broaden access to cardiac screening in different care settings and help identify patients who may require further evaluation.

“UltraSight combines clinical evidence with a scalable commercial model in a market constrained by access and workforce shortages,” said Dudi Klein, Alive co-founder and managing partner. “We believe the company has developed technology, leadership, and strategic collaborations that position it to support the evolution of cardiac workflows across care settings.”

Professor Rafi Beyar, an interventional cardiologist and general partner at Alive, said the technology could also play a role in structural heart disease, where access to real-time cardiac imaging can be critical for diagnosis and treatment.

UltraSight also recently appointed Rick Geoffrion as chairman of its board. Geoffrion has more than 30 years of experience in cardiovascular devices, including interventional cardiology, circulatory support, structural heart and commercialization.

“UltraSight is working to address an unmet need that has been a contributing constraint to the scale-up of advancements in cardiac care for the last 20 years; current access to reliable ultrasound imaging both for diagnosis and treatment remains dependent on a scarce group of experts,” Geoffrion said.

“This financing positions UltraSight to scale that foundation and extend the impact of an AI-guided cardiac workflow platform across cardiovascular care.”

The board will also add Klein, Star51 Capital founding managing partner Tal Wenderow and Deep Insight managing partner Barak Ben-Eliezer.

UltraSight said its broader goal is to allow health systems to expand access to cardiac imaging while keeping interpretation and reporting under physician oversight.

Mayo Clinic, which has a financial interest in the technology referenced by UltraSight, said any revenue it receives will support its not-for-profit mission in patient care, education and research.